跳到正文
原文
Endpoints News 生物医药· ENDPOINTS·· 28 天前AI 评分31

Lycia Therapeutics 定价 3.18 亿美元 IPO;Merck sac-TMT 试验提前终止

Lycia's $318M IPO; Merck sac-TMT trial stopped early

AI 导读

Lycia Therapeutics 定价发行 3.175 亿美元首次公开募股(IPO)。Merck 的 sac-TMT 临床试验因未披露原因提前终止。Hexagon Bio、Mineralys Therapeutics 和 Arbor Biotechnologies 的相关新闻因原文被付费墙遮挡,无法提取具体细节。

正文

Plus news about Hexa­gon Bio, Min­eralys Ther­a­peu­tics and Ar­bor Biotech­nolo­gies.

Ly­cia prices $317.5 mil­lion IPO: Ly­cia Ther­a­peu­tics, a com­pa­ny found­ed by No­bel Prize win­ner Car­olyn …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news